HC Wainwright Issues Pessimistic Outlook for ASMB Earnings

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Equities researchers at HC Wainwright reduced their Q1 2026 earnings per share estimates for Assembly Biosciences in a note issued to investors on Thursday, March 26th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will earn ($0.73) per share for the quarter, down from their previous forecast of ($0.50). HC Wainwright has a “Buy” rating and a $50.00 price objective on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is ($6.87) per share. HC Wainwright also issued estimates for Assembly Biosciences’ Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.69) EPS, Q4 2026 earnings at $3.51 EPS, FY2026 earnings at $1.61 EPS, FY2027 earnings at ($0.64) EPS, FY2028 earnings at $0.32 EPS and FY2029 earnings at ($2.83) EPS.

Assembly Biosciences (NASDAQ:ASMB) last issued its earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 EPS for the quarter, topping the consensus estimate of ($0.51) by $2.99. The company had revenue of $42.47 million during the quarter, compared to the consensus estimate of $7.42 million. Assembly Biosciences had a negative return on equity of 5.63% and a negative net margin of 8.47%.

Several other equities analysts also recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Wednesday, January 21st. Wall Street Zen upgraded shares of Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $41.75.

Assembly Biosciences Stock Performance

ASMB opened at $27.70 on Monday. The stock’s fifty day simple moving average is $27.93 and its 200 day simple moving average is $29.84. Assembly Biosciences has a 1-year low of $7.75 and a 1-year high of $39.71. The stock has a market cap of $439.32 million, a PE ratio of -37.43 and a beta of 1.11.

Institutional Trading of Assembly Biosciences

Several institutional investors have recently added to or reduced their stakes in the company. Farallon Capital Management LLC acquired a new position in Assembly Biosciences in the 3rd quarter valued at $31,426,000. RA Capital Management L.P. acquired a new stake in shares of Assembly Biosciences during the third quarter worth $26,122,000. Commodore Capital LP acquired a new stake in shares of Assembly Biosciences during the third quarter worth $25,600,000. Janus Henderson Group PLC boosted its position in shares of Assembly Biosciences by 11.3% in the fourth quarter. Janus Henderson Group PLC now owns 837,925 shares of the biopharmaceutical company’s stock valued at $28,540,000 after acquiring an additional 85,299 shares during the period. Finally, Paradigm Biocapital Advisors LP acquired a new position in shares of Assembly Biosciences in the fourth quarter valued at about $22,625,000. 19.92% of the stock is currently owned by institutional investors.

Assembly Biosciences News Summary

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: Wall Street Zen upgraded ASMB to a “Strong‑Buy,” which supports bullish investor sentiment and could attract buying interest. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy rating with a $50 target and raised several multi‑year forecasts (notably FY2026 and FY2028), signaling conviction in ASMB’s longer‑term outlook despite near‑term variability. Article Title
• Neutral Sentiment: Recent compilation of research analyst Q1 earnings predictions provides a range of expectations investors can use to position ahead of the quarterly report; this keeps Q1 results a near‑term catalyst. Article Title
• Negative Sentiment: HC Wainwright trimmed near‑term EPS estimates (Q1–Q3 2026) and cut FY2027 and FY2029 forecasts, which may be pressuring the stock as it raises questions about short‑term profitability and execution risk. MarketBeat ASMB coverage

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.